Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion

Core Insights - Voyageur Pharmaceuticals Ltd. is expanding its board of directors by appointing two experienced Wall Street executives to enhance its access to U.S. capital markets and attract American investments for growth in the diagnostic imaging sector [1][2][3] Board Expansion - The new directors possess extensive experience in U.S. public offerings, capital raises, and regulatory compliance, which will help Voyageur transition from the TSX Venture Exchange to the U.S. markets [2][3] - Jeffrey J. Kraws has over 35 years of experience in leading capital raises and IPOs for pharmaceutical firms, expected to leverage his network to enhance Voyageur's equity story [3][6] - Christopher A. Van Buren brings over three decades of leadership experience and expertise in risk management, which will strengthen Voyageur's governance and compliance with U.S. regulations [4][6] Strategic Vision - The board expansion aligns with Voyageur's goal of becoming the first contrast media company with a secure supply chain of domestically produced products, ensuring long-term supply chain security for North America [5] - Voyageur is advancing its feasibility studies for the Frances Creek Barium Contrast project and the Oklahoma iodine feasibility study, aiming to become a vertically integrated radiology drug company [5][12] Business Model - Voyageur focuses on developing high-performance barium and iodine Active Pharmaceutical Ingredients (API) for imaging contrast agents, with plans to transition into a high-margin domestic manufacturer [9][10] - The company aims to control all primary input costs from sourcing raw materials to final production, embodying the "Earth to Bottle" strategy to ensure quality and cost efficiency [12][11]